News

See More News

ARLG in the News

As Superbugs Flourish, Bacteriophage Therapy Recaptures Researchers’ Interest, JAMA Network, February 22, 2023

Adaptive Phage Therapeutics Announces First Patient Dosed in the PHAGE Clinical Trial Evaluating Phage Therapy in Cystic Fibrosis-related Respiratory Infection, January 12, 2023

Study Evaluates Biomarker to Help Curb Unnecessary Antibiotic Use, December 13, 2022

NIH-Supported Clinical Trial of Phage Therapy for Cystic Fibrosis Begins, October 4, 2022

Dr. Robin Patel Selected for 2022 Hamao Umezawa Memorial Award, March 8, 2022

Local VA Infectious Disease Expert Selected to Lead Emerging Infectious Diseases Response, March 2, 2022

Duke doctor: Superbugs are the next pandemic. What the US must do to combat them. Op-ed, Raleigh News & Observer, Charlotte Observer, Durham Herald-Sun. January 20, 2022

Adaptive Phage Therapeutics Announces Strategic Agreement with ARLG to Support Phase 1b/2 Cystic Fibrosis Study, November 2, 2021

Carbapenem-resistant Enterobacterales in the USA, March 6, 2020

Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study, March 6, 2020

NIH Renews Funding for the Antibacterial Resistance Leadership Group, NIAID, December 13, 2019

Research Network Based at DCRI Awarded up to $102.5M for Work on Antibacterial Resistance, DCRI, December 13, 2019

Duke Clinical Research scores $102.5M federal award for its work on antibacterial resistance, WRAL TechWire, December 2019.

Duke Clinical Research Institute lands $100M+ federal contract, Triangle Business Journal, December 2019.

Licensing Nucleic Acid Amplification Tests for Extragenital Gonorrhea and Chlamydia: Innovative Science and a Call to Arms. Clinical Infectious Diseases editorial authors praise the ARLG MASTER-GC study for its clinical relevance and collaborative approach to the development of diagnostics. November 2019.

Reviewing data collected by the ARLG, FDA clears first diagnostic tests for extragenital testing for chlamydia and gonorrhea, FDA, May 23, 2019

The ARLG and COMBACTE join forces to create gloabal alliance against antibiotic resistance, DCRI, April 13, 2019